FPI Move To China From India Will Last For Less Than 30 Days, Says Helios Capital's Samir Arora
The outflow of foreign institutional capital from Indian equities and into China is "fleeting" and a result of temporary adjustment by large fund houses to reposition in an underweight market, according to Samir Arora, founder of Helios Capital.
"If someone wants to invest in China with a fixed amount of money, there are many places to move out from," Arora told NDTV Profit, counting Taiwan and South Korea among probable hubs.
He said for the short term, hedge funds and other institutional investors that were "extreme" underweight on China will now be ploughing into mainland stocks. Change in weightage in emerging market benchmarks will have a marginal impact, added Arora.

Samir Arora, founder and fund manager, Helios Capital. (Source: NDTV Profit)
"India in absolute terms, if not relative, better off if equities in China do well," Arora said. He explained that there was a cautious view on Indian valuations that were trading at a higher premium over emerging market peers all while China was doing poorly.
"If all other markets like the US and China do well, then there is less reluctance on the part of Indian mutual funds sitting on cash (to invest). We may be less up, but not down compared to the rest," the fund manager said.
He also noted that last week's decline in Indian stocks was also influenced by the market regulator SEBI's new curbs in the derivatives segment and not just a reaction to events in China.
He said the trend of exit-India-enter-China will last for less than 30 days as long-term capital deployment of overseas investors will stay intact.
"It's possible new money goes to China and it may outperform India for some time, but it's like value stocks outperform growth stocks for some time. It's unlikely that we will be negative," he said.
Arora also noted that domestic investors have been lapping up shares offloaded by foreigners as evident by daily data shared by the exchanges, showing a clear buy-on-dips strategy.
India Vs. China—Samir Arora Weighs In|Watch
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.